Lebwohl, M., Bachelez, H. , Gordon, K., Wu, T., Chen, M., Kaplan, B. and Papp, K. 2023. Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s258. DOI:https://doi.org/10.25251/skin.7.supp.258.